PPARγ as a therapeutic target in central nervous system diseases

被引：91
作者：
Sundararajan, Sophia
Jiang, Qingguang
Heneka, Michael
Landreth, Gary
机构：
[1] Case Western Reserve Univ, Sch Med, Alzheimers Res Lab, Dept Neurol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA
[3] Univ Munster, Dept Neurol, D-14849 Munster, Germany
来源：
NEUROCHEMISTRY INTERNATIONAL | 2006年 / 49卷 / 02期
关键词：
Alzheimer's disease; stroke; multiple sclerosis; Parkinson's disease; amytrophic lateral sclerosis;
D O I：
10.1016/j.neuint.2006.03.020
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Diseases of the central nervous system present a challenge for the development of new therapeutic agents. Nuclear receptors are ligand-activated transcription factors that have proven to be valuable targets for development of new drugs owing to their ability to directly regulate gene expression. The nuclear receptor, peroxisome proliferator-activated receptor gamma (PPAR gamma), has been investigated for its action in ameliorating the development and progression of a number of CNS diseases. PPAR gamma agonists exhibit potent anti-inflammatory effects and appear to have direct neuroprotective actions. PPAR gamma agonists have been shown to be efficacious in animal models of Alzheimer's disease, stroke, multiple sclerosis, Parkinson's disease and amyotrophic lateral sclerosis. The availability of FDA-approved agonists of this receptor will facilitate the rapid translation of these findings into clinical trials for a number of CNS diseases. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码：136 / 144
页数：9
相关论文
共 85 条
[71]   A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia [J].
Shimazu, T ;
Inoue, I ;
Araki, N ;
Asano, Y ;
Sawada, M ;
Furuya, D ;
Nagoya, H ;
Greenberg, JH .
STROKE, 2005, 36 (02) :353-359
[72]   Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: Implications for multiple sclerosis [J].
Storer, PD ;
Xu, JH ;
Chavis, J ;
Drew, PD .
JOURNAL OF NEUROIMMUNOLOGY, 2005, 161 (1-2) :113-122
[73]   Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia [J].
Sundararajan, S ;
Gamboa, JL ;
Victor, NA ;
Wanderi, EW ;
Lust, WD ;
Landreth, GE .
NEUROSCIENCE, 2005, 130 (03) :685-696
[74]   Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons [J].
Uryu, S ;
Harada, J ;
Hisamoto, M ;
Oda, T .
BRAIN RESEARCH, 2002, 924 (02) :229-236
[75]   Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone - A preliminary study [J].
Watson, GS ;
Cholerton, BA ;
Reger, MA ;
Baker, LD ;
Plymate, SR ;
Asthana, S ;
Fishel, MA ;
Kulstad, JJ ;
Green, PS ;
Cook, DG ;
Kahn, SE ;
Keeling, ML ;
Craft, S .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2005, 13 (11) :950-958
[76]   Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size [J].
Wayman, NS ;
Hattori, Y ;
Mcdonald, MC ;
Mota-Filipe, H ;
Cuzzocrea, S ;
Pisano, B ;
Chatterjee, PK ;
Thiemermann, C .
FASEB JOURNAL, 2002, 16 (09) :1027-1040
[77]   A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity [J].
Weggen, S ;
Eriksen, JL ;
Das, P ;
Sagi, SA ;
Wang, R ;
Pietrzik, CU ;
Findlay, KA ;
Smith, TE ;
Murphy, MP ;
Butler, T ;
Kang, DE ;
Marquez-Sterling, N ;
Golde, TE ;
Koo, EH .
NATURE, 2001, 414 (6860) :212-216
[78]   Peroxisome proliferator-activated receptor γ and metabolic disease [J].
Willson, TM ;
Lambert, MH ;
Kliewer, SA .
ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 :341-367
[79]  
Yan Q, 1997, J COMP NEUROL, V378, P135
[80]  
Yan Q, 2003, J NEUROSCI, V23, P7504
123456789